Infliximab therapy in pulmonary sarcoidosis [1]

American Journal of Respiratory and Critical Care Medicine

Volumn 176, Issue 4, 2007, Pages 417-

  Kähler, Christian M ^a   Heininger, Peter ^a   Loeffler Ragg, Judith ^a   Vogelsinger, Helene ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

INFLIXIMAB; PLACEBO;

CLINICAL TRIAL; COHORT ANALYSIS; DRUG EFFICACY; DRUG INDICATION; HUMAN; IMMUNOTHERAPY; LETTER; LUNG SARCOIDOSIS; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RESIDUAL VOLUME; TOTAL LUNG CAPACITY; VITAL CAPACITY;

EID: 34547939328     PISSN: 1073449X     EISSN: 15354970     Source Type: Journal    
DOI: 10.1164/ajrccm.176.4.417     Document Type: Letter

References (3)

1. Baughman RP, Drent M, Kavuru M, Judson MA, Costabel U, du Bois R, Albera C, Brutsche M, Davis G, Donohue JF, et al. Infliximab therapy in patients with chronic sarcoidosis and pulmonary involvement. Am J Respir Crit Care Med 2006;174:795-802.
2. Dunn TL, Watters LC, Hendrix C, Cherniack RM, Schwarz MI, King TE. Gas exchange at a given degree of volume restriction is different in sarcoidosis and idiopathic pulmonary fibrosis. Am J Med 1988;85:221-224.
3. O'Shea FD, Marras TK, Inman RD. Pulmonary sarcoidosis developing during infliximab therapy. Arthritis Rheum 2006;55:978-981.